↓ Skip to main content

Sanchi for acute ischaemic stroke

Overview of attention for article published in Cochrane database of systematic reviews, October 2008
Altmetric Badge

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
52 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Sanchi for acute ischaemic stroke
Published in
Cochrane database of systematic reviews, October 2008
DOI 10.1002/14651858.cd006305.pub2
Pubmed ID
Authors

Xiaoyan Chen, Muke Zhou, Qifu Li, Jie Yang, Yun Zhang, Dongping Zhang, Shaugyan Kong, Dong Zhou, Li He

Abstract

Currently very few drugs are supported for routine use for acute ischaemic stroke. Sanchi is one of the most widely used herbal medicines for ischaemic stroke in China. To assess the effectiveness and safety of sanchi in the treatment of acute ischaemic stroke. We searched the Cochrane Stroke Group Trials Register (last searched January 2008), the Chinese Stroke Trials Register (searched February 2007), the Cochrane Complementary Medicine Field trials register (searched February 2007), the Chinese Cochrane Centre Controlled Trials Register (last searched February 2007). We also searched the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 1, 2007), MEDLINE (1966 to February 2007), EMBASE (1980 to February 2007), CINAHL (1982 to February 2007), AMED (1985 to February 2007), CNKI (1979 to February 2007), CBM-disc (1979 to February 2007), Chinese scientific periodical database of VIP INFORMATION (1989 to February 2007), Wanfang Data (1982 to February 2007), CISCOM (1980 to February 2007), and TCMLARS (1984 to February 2007). Randomised controlled trials comparing sanchi with placebo or no treatment for acute ischaemic stroke within 30 days of onset. Two review authors extracted data and assessed trial quality. Eight trials involving 660 participants were included. Seven of the eight studies were of poor quality. Follow-up time was less than one month in six trials. Only two trials provided data for the number of participants who were dead or dependent at the end of 28 days of treatment, indicating a significantly lower rate of death and dependency in the sanchi group than in the control group (relative risk (RR) 0.63, 95% confidence interval (Cl) 0.45 to 0.88). One trial reported higher Barthel index scores in the sanchi group. Pooled analysis of seven trials indicated that sanchi might improve neurological deficit more than control with a significant difference (RR 0.29, 95%Cl 0.18 to 0.47). The total case fatality rate was lower than 1% indicating that participants probably had mild strokes. Few adverse events were reported. Data were limited in respect of stroke recurrence and quality of life. Sanchi appears to be beneficial and safe for acute ischaemic stroke in this review, but the small sample and inferior quality of studies prevented a definite conclusion. More well-designed randomised controlled trials are required.

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 52 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 12 23%
Researcher 7 13%
Other 5 10%
Student > Ph. D. Student 5 10%
Student > Bachelor 4 8%
Other 6 12%
Unknown 13 25%
Readers by discipline Count As %
Medicine and Dentistry 20 38%
Nursing and Health Professions 5 10%
Neuroscience 3 6%
Social Sciences 2 4%
Computer Science 1 2%
Other 6 12%
Unknown 15 29%